These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2126475)

  • 1. Cost of surfactant replacement treatment for severe neonatal respiratory distress syndrome: a randomised controlled trial.
    Tubman TR; Halliday HL; Normand C
    BMJ; 1990 Oct; 301(6756):842-5. PubMed ID: 2126475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surfactant replacement therapy--economic impact.
    Pejaver RK; al Hifzi I; Aldussari S
    Indian J Pediatr; 2001 Jun; 68(6):501-5. PubMed ID: 11450378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: implications for nursing care.
    Sittlington N; Tubman R; Halliday HL
    Midwifery; 1991 Mar; 7(1):20-4. PubMed ID: 2011088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of surfactant replacement in preterm babies.
    Mugford M; Howard S
    Pharmacoeconomics; 1993 May; 3(5):362-73. PubMed ID: 10146887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic consequences of surfactant therapy.
    Eidelman AI
    J Perinatol; 1993; 13(2):137-9. PubMed ID: 8515307
    [No Abstract]   [Full Text] [Related]  

  • 6. A 2-year follow up of babies enrolled in a European multicentre trial of porcine surfactant replacement for severe neonatal respiratory distress syndrome. Collaborative European Multicentre Study Group.
    Robertson B; Curstedt T; Tubman R; Strayer D; Berggren P; Kok J; Koppe J; van Sonderen L; Halliday H; McClure G
    Eur J Pediatr; 1992 May; 151(5):372-6. PubMed ID: 1396894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact of porcine surfactant replacement (Curosurf) for severe neonatal respiratory distress syndrome.
    Tubman TR; Halliday HL; Normand C
    J Perinat Med; 1991; 19 Suppl 1():403-7. PubMed ID: 1779394
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost effectiveness of prevention and treatment of neonatal respiratory distress (RDS) with exogenous surfactant: what has changed in the last three decades?
    Mugford M
    Early Hum Dev; 2006 Feb; 82(2):105-15. PubMed ID: 16457971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of surfactant treatment on cost of neonatal intensive care: a cost-benefit analysis.
    Merritt TA; Hallman M; Vaucher Y; McFeeley E; Tubman TR
    J Perinatol; 1990 Dec; 10(4):416-9. PubMed ID: 2126034
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost implications of different approaches to the prevention of respiratory distress syndrome.
    Mugford M; Piercy J; Chalmers I
    Arch Dis Child; 1991 Jul; 66(7 Spec No):757-64. PubMed ID: 1863120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Collaborative European Multicenter Study Group.
    Pediatrics; 1988 Nov; 82(5):683-91. PubMed ID: 2903480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early or selective surfactant (colfosceril palmitate, Exosurf) for intubated babies at 26 to 29 weeks gestation. A European double-blind trial with sequential analysis. European Exosurf Study Group.
    Online J Curr Clin Trials; 1992 Nov; Doc No 28():[3886 words; 47 paragraphs]. PubMed ID: 1343614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surfactant replacement therapy: impact on hospital charges for premature infants with respiratory distress syndrome.
    Maniscalco WM; Kendig JW; Shapiro DL
    Pediatrics; 1989 Jan; 83(1):1-6. PubMed ID: 2909956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theoretical changes in neonatal hospitalisation costs after the introduction of porcine-derived lung surfactant ('Curosurf').
    Egberts J
    Pharmacoeconomics; 1995 Oct; 8(4):324-42. PubMed ID: 10155674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surfactant treatment and incidence of intraventricular haemorrhage in severe respiratory distress syndrome.
    McCord FB; Curstedt T; Halliday HL; McClure G; Reid MM; Robertson B
    Arch Dis Child; 1988 Jan; 63(1):10-6. PubMed ID: 3279916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. Danish-Swedish Multicenter Study Group.
    Verder H; Robertson B; Greisen G; Ebbesen F; Albertsen P; Lundstrøm K; Jacobsen T
    N Engl J Med; 1994 Oct; 331(16):1051-5. PubMed ID: 8090164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surfactant replacement therapy in premature babies with respiratory distress syndrome: factors affecting the response to surfactant and comparison of outcome from 1982-86 and 1987-91.
    Konishi M; Chida S; Shimada S; Kasai T; Murakami Y; Cho K; Fujii Y; Maeta H; Fujiwara T
    Acta Paediatr Jpn; 1992 Dec; 34(6):617-30. PubMed ID: 1285509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory distress syndrome in New Zealand: evidence from the OSIRIS trial of exogenous surfactant (Exosurf).
    Wach R; Darlow B; Bourchier D; Broadbent R; Knight D; Selby R
    N Z Med J; 1994 Jun; 107(980):234-7. PubMed ID: 8208494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated costs of different treatments of the respiratory distress syndrome in a large cohort of preterm infants of less than 30 weeks of gestation.
    Egberts J
    Biol Neonate; 1992; 61 Suppl 1():59-65. PubMed ID: 1391268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curosurf surfactant application on preterm babies with respiratory complications-health-economic benefits.
    Mihaylova A; Kristina K; Kasnakova P; Gueorguiev S; Gueorguieva P; Bakova D; Parahuleva N
    Afr Health Sci; 2024 Mar; 24(1):220-227. PubMed ID: 38962356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.